ASCO 2022 | OS and biomarker results from COMBAT: bipolar androgen therapy plus nivo for patients with mCRPC

Mark Christopher Markowski, MD, PhD, Johns Hopkins Medicine, Baltimore, MD, provides an update on the overall survival (OS) and biomarker results from a Phase II study of bipolar androgen therapy (BAT) plus nivolumab in patients with metastatic castrate-resistant prostate cancer (mCRPC). BAT combined with nivolumab led to a median overall survival of more than 2 years in heavily pretreated patients with mCRPC. In addition, BAT attenuated expression of MYC which correlated with better outcomes. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.